SAB Biotherapeutics, Inc. - 10-Q Filing

SAB Biotherapeutics reports Q3 financial results including details on Series A and B preferred stock, warrant valuations, and clinical trial expense structures.

SEC EDGAR ·

Tickers: $SABS

Read the full article at SEC EDGAR

More Regulatory news